Ratings by Piper Sandler (Danielle Brill)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/30/2021 | Acceleron Pharma | XLRN | Downgrade | Neutral (Overweight) |
175.36 (178.75) |
1.93% | Details | |
| 3/2/2021 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/4/2021 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/27/2020 | Global Blood Therapeutics | GBT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/4/2020 | Keros Therapeutics | KROS | New Coverage | Overweight (N/A) |
29.55 (10.59) |
-64.16% | Details | |
| 3/3/2020 | FibroGen | FGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/5/2020 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2020 | Momenta Pharmaceuticals | MNTA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/28/2020 | Acceleron Pharma | XLRN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/13/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/10/2019 | Global Blood Therapeutics | GBT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2019 | Momenta Pharmaceuticals | MNTA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2019 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2019 | FibroGen | FGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/7/2019 | Alder Biopharm | ALDR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2019 | Glycomimetics | GLYC | Downgrade | Neutral (Overweight) |
9.25 (0.16) |
-98.27% | Details | |
| 5/28/2019 | FibroGen | FGEN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/7/2019 | GW Pharma | GWPH | Maintain | Overweight (N/A) |
|
Details | ||
| 5/2/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2019 | uniQure BV | QURE | New Coverage | Overweight (N/A) |
58.20 (48.45) |
-16.75% | Details | |
| 4/12/2019 | Glycomimetics | GLYC | New Coverage | Overweight (N/A) |
12.11 (9.25) |
-23.62% | Details | |
| 4/12/2019 | FibroGen | FGEN | New Coverage | Neutral (N/A) |
54.25 (9.71) |
-82.1% | Details | |
| 4/9/2019 | Zogenix, Inc. | ZGNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/6/2019 | Zogenix, Inc. | ZGNX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2018 | Zogenix, Inc. | ZGNX | New Coverage | Overweight (N/A) |
44.21 (26.68) |
-39.65% | Details | |
| 11/5/2018 | MorphoSys AG | MOR | New Coverage | Overweight (N/A) |
26.86 (18.96) |
-29.41% | Details | |
| 11/5/2018 | Momenta Pharmaceuticals | MNTA | New Coverage | Overweight (N/A) |
13.53 (52.48) |
287.88% | Details | |
| 11/5/2018 | GW Pharma | GWPH | New Coverage | Overweight (N/A) |
147.25 (218.96) |
48.7% | Details | |
| 11/5/2018 | Alkermes | ALKS | New Coverage | Neutral (N/A) |
40.83 (48.76) |
19.42% | Details | |
| 9/21/2018 | Acadia Pharmaceuticals | ACAD | Upgrade | Overweight (Neutral) |
19.11 (29.27) |
53.17% | Details | |
| 9/18/2018 | Acceleron Pharma | XLRN | Upgrade | Overweight (Neutral) |
52.04 (178.75) |
243.49% | Details | |
| 8/23/2018 | Global Blood Therapeutics | GBT | Maintain | Overweight (N/A) |
|
Details |
